MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence Multiple studies highlight fidaxomicin’s effectiveness across high-risk populations despite cost and access challenges, underscoring the need for education and stewardship to improve guideline adheren...

At #MADID2025, a clear theme emerged, highlighting fidaxomicin as the preferred treatment for C. difficile infection in patients at risk of recurrence. @mad-id.bsky.social #IDsky #MEDsky #Cdiffsky

Read all about it: www.contagionlive.com/view/mad-id-...

Sharing our work on #Cdiff published in ASHE Journal! 🎉 A review of 40 studies identified gastric acid suppressants, recent hospitalization, antibiotic exposure and certain comorbidities as independent predictors of healthcare-associated CDI. Kudos to the team! 🙌 #IDSky #Cdiffsky
shorturl.at/yA8Sw

@abhishekdp.bsky.social #cdiffsky

#cdiffsky